BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12381951)

  • 1. Vitamin K status in relation to bone metabolism in patients with renal failure.
    Małyszko J; Wołczyński S; Skrzydlewska E; Małyszko JS; Myśliwiec M
    Am J Nephrol; 2002; 22(5-6):504-8. PubMed ID: 12381951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
    López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
    Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Selected parameters of bone metabolism in hemodialyzed and peritoneally dialyzed patients].
    Małyszko J; Zbroch E; Wołczyński S; Myśliwiec M
    Przegl Lek; 2000; 57(12):711-3. PubMed ID: 11398592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants.
    Withold W; Friedrich W; Degenhardt S
    Clin Chim Acta; 1997 May; 261(2):105-15. PubMed ID: 9201430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procollagen I carboxyterminal propeptide (PICP) as a bone formation marker and carboxyterminal telopeptide of type I collagen (ICTP) as a bone degradation marker in children with chronic renal failure under conservative therapy.
    Polak-Jonkisz D; Zwolińska D; Bednorz R; Owczarek H; Szymańska A; Nahaczewska W
    Med Sci Monit; 2003 Jan; 9(1):CR19-23. PubMed ID: 12552245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
    Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
    Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum osteocalcin in children with chronic renal insufficiency].
    Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
    Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation between osteocalcin and bone histomorphometry in children with chronic renal failure].
    Weglarska J; Ziółkowska H; Pańczyk-Tomaszewska M; Sieniawska M
    Pediatr Pol; 1995 Dec; 70(12):1011-5. PubMed ID: 8649939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients.
    Małyszko J; Wołczyński S; Zbroch E; Brzósko S; Małyszko J; Myśliwiec M
    Nephron; 2002 Mar; 90(3):282-9. PubMed ID: 11867949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms.
    Magnusson P; Sharp CA; Magnusson M; Risteli J; Davie MW; Larsson L
    Kidney Int; 2001 Jul; 60(1):257-65. PubMed ID: 11422759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineral-bone metabolism markers in young hemodialysis patients.
    Osorio A; Ortega E; Torres JM; Sanchez P; Ruiz-Requena E
    Clin Biochem; 2011 Dec; 44(17-18):1425-8. PubMed ID: 21933667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
    Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
    Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients.
    Małyszko J; Małyszko JS; Pawlak K; Wołczyński S; Myśliwiec M
    Adv Med Sci; 2006; 51():69-72. PubMed ID: 17357281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary deoxypyridinoline excretion for the evaluation of bone turnover in chronic renal failure.
    Coen G; Mantella D; Calabria S; Sardella D; Manni M; Fassino V; D'Anello E; Giustini M; Taggi F
    Am J Nephrol; 2000; 20(4):283-90. PubMed ID: 10970981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃.
    Rossini M; Gatti D; Viapiana O; Fracassi E; Idolazzi L; Zanoni S; Adami S
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E622-6. PubMed ID: 22298802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate kinetics in patients undergoing continuous ambulatory peritoneal dialysis: relations to dynamic bone histomorphometry, osteocalcin and parathyroid hormone.
    Joffe P; Hyldstrup L; Heaf JG; Pødenphant J; Henriksen JH
    Am J Nephrol; 1992; 12(6):419-24. PubMed ID: 1292341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.